Streetbeat News

Earnings

FDMT

4D Molecular Therapeutics (Nasdaq: FDMT) reported its Q3 2024 financial results, operational highlights, and upcoming milestones. The company is focused on genetic medicines for large market diseases.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

ICAD

iCAD, Inc. reported its financial results for Q3 2024, highlighting its role as a leader in AI-powered breast health solutions.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

ECOR

electroCore reported its third quarter 2024 financial results, highlighting record quarterly revenues. This growth was driven by a 75% year-over-year increase in Rx gammaCore™ sales within the VA/DoD and a 147% rise in Truvaga™ sales.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

CVV

CVD Equipment Corporation (NASDAQ: CVV) reported a 31.4% increase in revenue for Q3 2024, reaching $8.2 million, which improved operating performance and system gross margins.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

OXBR

Oxbridge Re Holdings Limited (NASDAQ: OXBR) reported its third quarter 2024 results, focusing on its business in tokenized Real-World Assets and reinsurance solutions in the Gulf Coast region.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

ACELYRIN

ACELYRIN, INC. has released its financial results for the third quarter of 2024 and announced that topline data from its Phase 2b/3 trial of izokibep for treating non-infectious non-anterior uveitis is expected in December 2024.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

BTM

Bitcoin Depot Inc. (NASDAQ:BTM) held its Q3 2024 earnings conference call on November 13, 2024. Key participants included CEO Brandon Mintz, CFO Glen Leibowitz, and COO Scott Buchanan.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

TTEK

Tetra Tech, Inc. reported record fiscal 2024 and fourth quarter results, with a 15% year-over-year increase in revenue to $5.20 billion and a 40% increase in operating income to $501 million.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

VXRT

Vaxart has provided a business update and reported its Q3 2024 financial results. The company expects to complete enrollment for its COVID-19 Phase 2b study in November 2024. Vaxart is in a solid financial position to achieve regulatory and clinical milestones.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

ADAP

Adaptimmune Therapeutics (NASDAQ: ADAP) reports Q3 2024 financial updates, highlighting the launch of Tecelra® with 9 treatment centers and the first patient apheresed. The company plans a 33% headcount reduction in Q1 2025 to save $300 million over four years, aiming for breakeven by 2027. Total liquidity at the end of Q3 was $186.1 million.

Portfolio Pulse from

November 13, 2024 | 9:15 pm